Canon Medical Offers New Liver Reporting Tool for Ultrasound

December 1, 2020

Canon Medical reminds us that liver disease is one of the major challenges in imaging today, and accurately determining compensated advanced chronic liver disease (cACLD) is extremely important in order to define the right treatment path.

The recently updated guidelines from Society of Radiologists in Ultrasound introduced the “Rule of Four,” a standardized method of using four different levels of shear wave elastography-based liver stiffness to assess the probability of cACLD. To help easily and accurately determine cut off values, Canon Medical Systems USA, Inc.’s premium AplioTM i-series ultrasound platform is now available with software to display the calculated measurement averages from multiple samples of the liver, customizable based on the “Rule of Four.”

The program uses measurements obtained with Shear Wave Elastography, Canon Medical’s technology that provides a quantitative measure and dynamic visual display of tissue stiffness in the liver. In addition, the system provides standard deviation and interquartile range (IQR) data, as well as a simple visual propagation map, to ensure accurate and confident application of the “Rule of Four” to determine cACLD and for the assessment of other liver pathologies.

“The new guidelines from SRU reinforce the importance of quickly and accurately determining cACLD, so that clinicians can chart the right course for patient care,” said Dan Skyba, managing director, Ultrasound Business Unit, Canon Medical Systems USA, Inc. “At Canon Medical, it doesn’t get much easier than automatically calculating that average measurement of tissue stiffness, with our Shear Wave Elastography plus this new liver reporting tool.”

The Aplio i-series will be showcased at this year’s virtual Radiological Society of North America (RSNA), at Canon Medical’s unique, immersive booth experience.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version